Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer

Cliniques universitaires Saint-Luc- Université Catholique de Louvain40 enrolled

Overview

The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to: generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer * perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors * evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options * evaluate biomarkers of drug sensitivity * study primary and secondary (acquired) resistance in these models

Study Type

OBSERVATIONAL

Enrollment

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

Local biopsy in the tumorPROCEDURE

A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.

Medical Language ↔ Plain English

Inclusion Criteria: * In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent * Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available * Follow-up data should be available * Patients with recurrent disease are allowed * Written informed consent

Outcomes

Primary Outcomes

Identification of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with immunohistochemistry (KI67) on FFPE (fixation followed by paraffin embedding) slides

Identification of the biomarkers of new cancer therapies for head and neck

Time frame: 10 years

Secondary Outcomes

Characterization of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with genetic techniques

Time frame: 10 years

Central Contacts

Aline Gillain, MedSciences

CONTACT

00322764 aline.gillain@uclouvain.be

Sandra Schmitz, MD, PhD